CpG Island Methylator Phenotype in Adrenocortical Carcinoma: Fact or Fiction?
Yi Liu-Chittenden and Electron Kebebew
Endocrine Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892-1201
A drenocortical tumors are common and most are asymptomatic, benign adrenocortical adenomas (ACAs), but a significant number of patients undergo ad- renalectomy to exclude an adrenocortical carcinoma (ACC) diagnosis (1). Patients with ACC have a poor but variable prognosis (2). The Weiss criterion has been used for localized adrenocortical tumors to histologically dis- tinguish between ACA and ACC. A Weiss score of 0-2 is considered benign, whereas a Weiss score of 3-9 is con- sidered malignant. Molecular or genomic prognostic markers that can clearly distinguish between low-risk and high-risk ACC tumors for recurrence have impor- tant clinical ramifications, especially when considering adjuvant therapy with mitotane in patients with stage I and II ACC (3).
Over the last decade, with the application of advanced high throughput genomic technology, our understanding of adrenocortical tumorigenesis has improved. For exam- ple, through genome-wide gene expression profiling, it was found that overexpression of the IGF 2 (IGF2), un- derexpression of the nonprotein coding RNA H19, acti- vation of Wnt- B-catenin signaling, and inactivation of the tumor suppressor p53 are associated with ACC. Through genome-wide microRNA profiling, it has been observed that overexpressed microRNA, such as miR-483-5p, and underexpressed microRNA, such as miR-195 and miR- 335, can distinguish ACC from ACA and serve as diag- nostic and prognostic markers (4).
In 2012, several studies on the epigenetic changes as- sociated with adrenocortical tumors have been reported. Epigenetic changes refer to heritable modifications to the genome that change gene expression but do not alter the DNA sequence (5). Rechache et al. (6) reported the first
genome-wide DNA methylation profiling in normal ad- renal cortex, and benign and malignant adrenocortical tumors. Methylation profiling of normal, ACA, primary ACC, and metastatic ACC showed unique methylation patterns, and showed that primary and metastatic ACC samples were globally hypomethylated compared with normal and benign samples. Through integrated analysis of genome-wide gene expression and methylation profil- ing, 52 hypermethylated and down-regulated genes in ACC were identified, which suggests that gene methyl- ation status may be an important regulator of gene ex- pression in ACC. Fonseca et al. (7) also analyzed the ge- nome-wide methylation profiles of normal, benign, and malignant adrenocortical samples. They identified 212 CpG islands in the promoter regions that were signifi- cantly hypermethylated in ACC and further validated six of the top 50 genes that might be important in the patho- genesis of ACC.
In this issue of the JCEM, Barreau et al. (8) report on their analysis of DNA methylation in adrenocortical tu- mors from a distinct point of view. Their study focused on the methylation profiles of the CpG islands in the pro- moter regions. CpG islands are genomic regions of larger than 500 bp, with more than 55% of the nucleotides com- posed of CpG dinucleotides (9). Unlike the two previous studies, they examined only tumor tissues, which included 84 ACA and 51 ACC samples. Their analysis also focused on the molecular classification of ACC based on patient outcome. The investigators report two important results. First, ACCs were more globally hypermethylated than ACAs at the CpG islands in the promoter regions, which was consistent with findings in previous studies (6, 7). Second, ACC samples could be categorized into two dif-
Abbreviations: ACA, Adrenocortical adenoma; ACC, adrenocortical carcinoma; CIMP, CpG island methylator phenotype.
Copyright @ 2013 by The Endocrine Society doi: 10.1210/jc.2012-4063 Received December 1, 2012. Accepted December 6, 2012.
For article see page E174
ferent groups based on their methylation profiles. One of them exhibited only slightly higher methylation than ACAs, which they named the “non-CIMP (CpG island methylator phenotype)” group; the other one exhibited higher methylation than ACAs and the “non-CIMP” group, which they termed the “CIMP” group. The “CIMP” group was further divided into “CIMP-low” and “CIMP-high” subgroups based on their differential hy- permethylation profile. CIMP was first described in colo- rectal cancer to depict a tumor-specific DNA hypermeth- ylation phenotype that can distinguish different tumor groups (10). There have been several reports on CIMP in gastric, ovarian, liver, and lung cancers and leukemia, sug- gesting that CIMP might be a universal phenotype in can- cer (11). This is the first paper that describes the presence of CIMP in ACC. Consistent with their groupings, CIMP and non-CIMP patients showed significantly different prognosis, with longer survival in non-CIMP patients. Previously, the same group reported, based on gene ex- pression analysis, that ACAs could be distinguished from ACCs, and that ACCs could be divided into two groups- one with a good prognosis and the other with a poor prog- nosis (12). The poor prognosis group was further divided into three subgroups, which were associated with inacti- vated p53, activated ß-catenin, or an “unknown” molec- ular characteristics group. It is interesting to see that for each group categorized by gene expression, the methyla- tion-based groupings were also different. These data sug- gest that differential methylation in the CpG promoter regions of genes might be functionally important and clas- sification based on methylation may be a marker for prog- nosis in patients with ACC.
There are some limitations to the study. The authors used the Infinium HumanMethylation27 Beadchip to study the methylation patterns of CpG islands in the prox- imal promoter regions of 14,475 genes (8). However, the coverage of this platform is not completely genome-wide. There are 20,000 to 25,000 protein-coding genes in the human genome (13). Only 70% of the gene promoters are associated with a CpG island, and only 6.8% of CpG dinucleotides are in CpG islands (14, 15). For example, in colon cancer, it has been shown that neither the promoter nor the CpG islands, but sequences up to 2 kb distant from the CpG islands (CpG island shores) have the most meth- ylation changes (16). Thus, by looking only at the CpG islands at the promoter region of a subset of genes, a lot of information could be missed, and thus the conclusion of the presence of CIMP in ACC is not conclusive.
Although CIMP has been described in various cancers, there is also not yet a consensus definition for it. Some investigators have suggested several criteria to define CIMP, which include a quantitative analysis, a group of
genes that are hypermethylated in high frequency, and that the methylation should be tumor-specific (17). Barreau et al. (8) in their study used quantitative methylation profiling, described a differential methylation phenotype in ACC sam- ples, and divided them into two groups (non-CIMP and CIMP), and then two more subgroups (CIMP-low and CIMP-high). However, rather than featuring a group of marker genes that can define a CIMP phenotype, the meth- ylation patterns in these groups were more universal. Because only adrenocortical tumor samples were analyzed in their study, it would also be important to make sure that the meth- ylation differences observed were specific to ACC by includ- ing normal adrenal cortex samples in the analysis.
Finally, through integrated analysis of methylation profiling and gene-expression analysis, a list was compiled of the top 25 genes, which showed inverse correlation between their methylation and expression. Among other genes with tumor suppressor function, H19 was identi- fied, which has consistently been observed to be underex- pressed and hypermethylated in ACCs. This served as a validation for their analysis. It would be informative if the fold changes in methylation and gene expression were pro- vided for each top gene identified. Rechache et al. (6) per- formed a similar comparison in ACC and ACA samples and identified 52 genes that were hypermethylated and down-regulated, but there appears to be no overlap be- tween the top genes identified in these two studies. The discrepancy may be due to the different platforms used for the methylation profiling because the HumanMethyla- tion450 BeadChip used in the study by Rechache et al. (6) provides a more comprehensive coverage of the genome with 17 times more CpG sites than the soon-to-be discon- tinued HumanMethylation27 BeadChip used in the study by Barreau et al. (8).
Overall, the study performed by Barreau et al. (8) ad- vances our knowledge on the role of epigenetic changes in ACC and suggests for the first time the presence of CIMP in ACC. They show differential methylation phenotype in ACC samples, which was associated with prognosis. Fu- ture studies are needed to confirm this discovery and to understand the role of CIMP in ACC.
Acknowledgments
Address all correspondence and requests for reprints to: Electron Kebebew, Endocrine Oncology Branch, National Cancer Insti- tute, 10 Center Drive, MSC 1201, Bethesda, Maryland 20892- 120. E-mail: kebebewe@mail.nih.gov.
This research was supported by the Intramural Research Pro- gram, Center for Cancer Research, National Cancer Institute, National Institutes of Health.
Disclosure Summary: The authors have nothing to disclose.
References
1. Grumbach MM, Biller BM, Braunstein GD, Campbell KK, Carney JA, Godley PA, Harris EL, Lee JK, Oertel YC, Posner MC, Schlechte JA, Wieand HS 2003 Management of the clinically inapparent ad- renal mass (“incidentaloma”). Ann Intern Med 138:424-429
2. Bilimoria KY, Shen WT, Elaraj D, Bentrem DJ, Winchester DJ, Kebebew E, Sturgeon C 2008 Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer 113:3130-3136
3. Fassnacht M, Libé R, Kroiss M, Allolio B 2011 Adrenocortical car- cinoma: a clinician’s update. Nat Rev Endocrinol 7:323-335
4. Jain M, Rechache N, Kebebew E 2012 Molecular markers of adre- nocortical tumors. J Surg Oncol 106:549-556
5. Berger SL, Kouzarides T, Shiekhattar R, Shilatifard A 2009 An op- erational definition of epigenetics. Genes Dev 23:781-783
6. Rechache NS, Wang Y, Stevenson HS, Killian JK, Edelman DC, Merino M, Zhang L, Nilubol N, Stratakis CA, Meltzer PS, Kebebew E 2012 DNA methylation profiling identifies global methylation differences and markers of adrenocortical tumors. J Clin Endocrinol Metab 97:E1004-E1013
7. Fonseca AL, Kugelberg J, Starker LF, Scholl U, Choi M, Hellman P, Åkerström G, Westin G, Lifton RP, Björklund P, Carling T 2012 Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors. Genes Chromosomes Cancer 51:949-960
8. Barreau O, Assié G, Wilmot-Roussel H, Ragazzon B, Baudry C, Perlemoine K, René-Corail F, Bertagna X, Dousset B, Hamzaoui N, Tissier F, de Reynies A, Bertherat J 2012 Identification of a CpG island methylator phenotype in adrenocortical carcinomas. J Clin Endocrinol Metab 98:174-184
9. Takai D, Jones PA 2002 Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci USA 99:3740- 3745
10. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP 1999 CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 96:8681-8686
11. Teodoridis JM, Hardie C, Brown R 2008 CpG island methylator phenotype (CIMP) in cancer: causes and implications. Cancer Lett 268:177-186
12. Ragazzon B, Libé R, Gaujoux S, Assié G, Fratticci A, Launay P, Clauser E, Bertagna X, Tissier F, de Reyniès A, Bertherat J 2010 Transcriptome analysis reveals that p53 and ß-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Res 70:8276-8281
13. 2004 Finishing the euchromatic sequence of the human genome. Nature 431:931-945
14. Rollins RA, Haghighi F, Edwards JR, Das R, Zhang MQ, Ju J, Bestor TH 2006 Large-scale structure of genomic methylation patterns. Genome Res 16:157-163
15. Saxonov S, Berg P, Brutlag DL 2006 A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc Natl Acad Sci USA 103:1412-1417
16. Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P, Cui H, Gabo K, Rongione M, Webster M, Ji H, Potash JB, Sabun- ciyan S, Feinberg AP 2009 The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-spe- cific CpG island shores. Nat Genet 41:178-186
17. Issa JP 2004 CpG island methylator phenotype in cancer. Nat Rev Cancer 4:988-993
THE ENDOCRINE SOCIETY®
Save the Date for Pediatric Endocrine Board Review (PEBR), September 24-25, 2013, Hyatt Regency New Orleans New Orleans, LA www.endo-society.org/CEU2013